180 related articles for article (PubMed ID: 11255268)
1. Mouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó K; Silva S; Pálóczi K; Domján G; Falus A
Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268
[TBL] [Abstract][Full Text] [Related]
2. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
Lattanzio G; Libert C; Aquilina M; Cappelletti M; Ciliberto G; Musiani P; Poli V
Am J Pathol; 1997 Sep; 151(3):689-96. PubMed ID: 9284817
[TBL] [Abstract][Full Text] [Related]
3. Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma.
Pattengale PK
Am J Pathol; 1997 Sep; 151(3):647-9. PubMed ID: 9284811
[No Abstract] [Full Text] [Related]
4. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
5. The use of animal models in multiple myeloma.
Libouban H
Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
[TBL] [Abstract][Full Text] [Related]
6. Disseminated growth of murine plasmacytoma: similarities to multiple myeloma.
Roschke V; Hausner P; Kopantzev E; Pumphrey JG; Riminucci M; Hilbert DM; Rudikoff S
Cancer Res; 1998 Feb; 58(3):535-41. PubMed ID: 9458102
[TBL] [Abstract][Full Text] [Related]
7. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.
Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES
Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
[TBL] [Abstract][Full Text] [Related]
9. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane.
Avcu F; Ural AU; Yilmaz MI; Ozcan A; Ide T; Kurt B; Yalcin A
Eur J Haematol; 2005 Jun; 74(6):496-500. PubMed ID: 15876253
[TBL] [Abstract][Full Text] [Related]
10. BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations.
Silva S; Kovalchuk AL; Kim JS; Klein G; Janz S
Cancer Res; 2003 Dec; 63(24):8656-63. PubMed ID: 14695177
[TBL] [Abstract][Full Text] [Related]
11. The SCID-hu myeloma model.
Epstein J; Yaccoby S
Methods Mol Med; 2005; 113():183-90. PubMed ID: 15968103
[TBL] [Abstract][Full Text] [Related]
12. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation.
McNeil N; Kim JS; Ried T; Janz S
Genes Chromosomes Cancer; 2005 Jun; 43(2):137-46. PubMed ID: 15751044
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells.
Qi CF; Zhou JX; Lee CH; Naghashfar Z; Xiang S; Kovalchuk AL; Fredrickson TN; Hartley JW; Roopenian DC; Davidson WF; Janz S; Morse HC
Cancer Res; 2007 Mar; 67(6):2439-47. PubMed ID: 17363561
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
15. Experimental plasmacytomas in relation to human multiple myeloma.
Azar HA
Ann Clin Lab Sci; 1974; 4(3):157-63. PubMed ID: 4825619
[No Abstract] [Full Text] [Related]
16. Gas chromatographic-mass spectrometric investigation of four commercial pristane (2.6.10.14-tetramethylpentadecane) preparations used for plasmacytoma induction in BALB/c mice.
Janz S; Birkenfeld T; Herzschuh R; Storch H
Arch Geschwulstforsch; 1989; 59(6):415-22. PubMed ID: 2596957
[TBL] [Abstract][Full Text] [Related]
17. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
18. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.
Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
Biochem Biophys Res Commun; 2004 Apr; 316(3):859-66. PubMed ID: 15033480
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on the origins of multiple myeloma and plasmacytomas in mice.
Potter M
Hematol Oncol Clin North Am; 1992 Apr; 6(2):211-23. PubMed ID: 1582969
[TBL] [Abstract][Full Text] [Related]
20. An in vivo model of human multiple myeloma bone disease.
Alsina M; Boyce BF; Mundy GR; Roodman GD
Stem Cells; 1995 Aug; 13 Suppl 2():48-50. PubMed ID: 8520511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]